Baudax Bio, Inc.
BXRX · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.01 | -0.00 | 0.05 |
| FCF Yield | -2,637.46% | -294.79% | -237.40% | -79.65% |
| EV / EBITDA | -0.08 | -0.20 | 0.02 | -1.21 |
| Quality | ||||
| ROIC | 613.30% | -47.69% | -144.88% | -38.41% |
| Gross Margin | -452.32% | -126.39% | -251.32% | 0.00% |
| Cash Conversion Ratio | 0.47 | 2.49 | 0.58 | 1.54 |
| Growth | ||||
| Revenue 3-Year CAGR | 37.05% | – | – | – |
| Free Cash Flow Growth | 43.78% | -10.69% | 13.26% | 18.47% |
| Safety | ||||
| Net Debt / EBITDA | -0.05 | 0.15 | 0.27 | 0.43 |
| Interest Coverage | -1.70 | -8.25 | -55.03 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.49 | 0.58 | 0.00 |
| Cash Conversion Cycle | -108.15 | 710.75 | -104.49 | 0.00 |